The major molecular response rate was 68% with asciminib and 49% with IS-TKIs (difference, 19% [95% CI, 10-28]; P .001). The Food and Drug Administration (FDA) has granted accelerated approval to ...
Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older. Background: The phase of chronic myeloid leukemia (CML) at diagnosis (dx) remains significant prognostic factor for the ...
According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...
Findings showed 30% of patients in the ponatinib arm achieved MRD-negative complete response rate at the end of the induction phase vs 12% of those in the imatinib arm. The Food and Drug ...
Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: One-year results of CA180–035 No significant financial relationships to disclose. This ...
(RTTNews) - Novartis (NVS) announced that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration for adult patients with newly diagnosed Philadelphia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback